Increased levels of specific proteins found in blood, namely C-reactive protein, lactate dehydrogenase, and total cholesterol, may predict the risk of mortality after acute exacerbation in idiopathic pulmonary fibrosis (IPF) patients, according to a retrospective study performed in Japan. The study, “Possible Serological Markers to Predict…
Certain Blood Protein Levels May Predict Mortality Risk After Sudden Disease Worsening in IPF, Study Suggests
Lung Therapeutics announced that it has raised $36 million in Series C financing to fund two projects, including a healthy volunteer Phase 1 clinical trial testing LTI-03, an experimental therapy for idiopathic pulmonary fibrosis (IPF). Currently approved therapies for IPF can slow disease progression, but cannot restore…
An exploratory Phase 2 study of Prometic‘s investigative oral therapy PBI-4050 in patients with idiopathic pulmonary fibrosis (IPF) showed “encouraging” results and no safety concerns, a study reports. Alone or in combination with Ofev (nintedanib), PBI-4050 was well-tolerated and showed…
The path to lung transplant is different for everyone, depending on their disease and how it progresses. My mom got very sick very fast. I found out that she would try to get listed, and 10 stressful weeks later, she had new lungs. What may be an extended…
As many as one in four people with idiopathic pulmonary fibrosis (IPF) may have the illness as a result of inhaling vapors, gas, dust, or fumes at work, according to an official statement by the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Such occupational…
As a patient living with idiopathic pulmonary fibrosis (IPF), I can’t count the number of times that close friends and family members have asked me to describe what this disease feels like. While I do my best to share my experience with IPF, I’ve been unsatisfied with the explanations I’ve…
There is no direct pathway when it comes to nutrition intervention for pulmonary fibrosis (PF), but a recent study found that nearly one-third of idiopathic PF (IPF) patients were malnourished, which indicates the intrinsic value of ensuring a proper…
This week, the world lost a champion. On June 3, 2019, Kim Fredrickson, a stoic and heroic inspiration to so many people living with pulmonary fibrosis (PF), died after nearly four months in the intensive care unit at UCSF Medical Center, where she was awaiting a life-saving…
Finding Employment that Fits Me
After being diagnosed with a devastating disease like idiopathic pulmonary fibrosis (IPF), life tends to come to a momentary halt. I was OK mentally after the initial diagnosis, but I then contracted respiratory syncytial virus (RSV) in January 2015. This secondary illness, caused by my IPF diagnosis,…
Plans for a Phase 2 clinical trial of brilaroxazine, the lead candidate by Reviva Pharmaceuticals to treat idiopathic pulmonary fibrosis (IPF), were the focus of a recent and successful meeting between company officials and the U.S. Food and Drug Administration (FDA), Reviva announced. During this pre-Investigational New Drug (IND) Application meeting, the regulatory…
Your PF Community
Recent Posts
- IPF drug Esbriet lowers risk of irregular heartbeats by nearly 90%, per study February 11, 2026
- Every patient’s journey with IPF is part of a unique mystery February 10, 2026
- New IPF therapy modulates genes tied to inflammation and scarring February 4, 2026
- My journey with PF and transplant means lifelong medical surveillance February 3, 2026
- Learning about the link between autoimmune disease and PF January 29, 2026
